Dyclonine HCl (536-43-6) is a topical anesthetic which has been used for oral and throat analgesia.1 Enhances neuronal mitochondrial function, potentiating respiration and providing protection against insults associated with neurodegenerative disorders.2 Inhibits aldehyde dehydrogenase ALDH3A1 resulting in accumulation of 4-hydroxynonenal, which renders head and neck squamous cell carcinoma cells sensitive to the cystine-glutamate antiporter inhibitor, sulfasalazine.3 Rescues frataxin deficiency in animal models as well as in buccal cells of patients with Friedreich’s Ataxia.4 Enhances the cytotoxic effect of proteasome inhibitors MG-1325 and bortezomb6 in cancer cells.
1) Groeben et al. (2001), Airway anesthesia alone does not explain attenuation of histamine-induced bronchospasm by local anesthetics: a comparison of lidocaine, ropivacaine, and dyclonine; Anesthesiology., 94 423
2) Boglarka et al. (2020), High-Throughput Small Molecule Screen Identifies Modulators of Mitochondrial Function in Neurons; iScience, 23 100931
3) Okazaki et al. (2018), Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells; Oncotarget, 9 33832
4) Sahdeo et al. (2014), Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedriech’s ataxia; Hum. Mol. Genet., 23 6848
5) Ju et al. (2009), Dyclonine and alverine citrate enhance the cytotoxic effects of proteasome inhibitor MG132 on breast cancer cells; J. Mol. Med., 23 205
6) Ju et al. (2014), Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells; Mol. Med. Rep., 10 2609